| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vomiting | 88 | 2024 | 133 | 14.160 |
Why?
|
| Antiemetics | 75 | 2023 | 95 | 13.310 |
Why?
|
| Nausea | 72 | 2024 | 110 | 11.950 |
Why?
|
| Antineoplastic Agents | 61 | 2023 | 628 | 7.670 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 40 | 2022 | 402 | 4.370 |
Why?
|
| Lung Neoplasms | 28 | 2023 | 584 | 3.400 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 20 | 2023 | 147 | 3.070 |
Why?
|
| Cisplatin | 37 | 2011 | 119 | 2.810 |
Why?
|
| Neurokinin-1 Receptor Antagonists | 18 | 2023 | 24 | 2.600 |
Why?
|
| Isoquinolines | 7 | 2016 | 32 | 2.380 |
Why?
|
| Quinuclidines | 7 | 2016 | 21 | 2.380 |
Why?
|
| Morpholines | 14 | 2011 | 86 | 2.320 |
Why?
|
| Serotonin Antagonists | 21 | 2011 | 30 | 2.100 |
Why?
|
| Dexamethasone | 26 | 2016 | 201 | 2.080 |
Why?
|
| Pyridines | 5 | 2017 | 98 | 2.070 |
Why?
|
| Neoplasms | 34 | 2017 | 1231 | 2.040 |
Why?
|
| Ondansetron | 22 | 2011 | 33 | 1.540 |
Why?
|
| Drug Therapy, Combination | 17 | 2017 | 451 | 1.330 |
Why?
|
| Humans | 143 | 2024 | 59424 | 1.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 6 | 2011 | 87 | 0.990 |
Why?
|
| Carcinoma, Small Cell | 5 | 2010 | 21 | 0.860 |
Why?
|
| Aged | 59 | 2018 | 13423 | 0.850 |
Why?
|
| Double-Blind Method | 24 | 2017 | 715 | 0.810 |
Why?
|
| Medical Oncology | 5 | 2023 | 57 | 0.800 |
Why?
|
| Middle Aged | 65 | 2018 | 16330 | 0.800 |
Why?
|
| Granisetron | 12 | 2003 | 12 | 0.740 |
Why?
|
| Male | 74 | 2020 | 27772 | 0.720 |
Why?
|
| Female | 75 | 2023 | 30753 | 0.690 |
Why?
|
| Treatment Outcome | 28 | 2018 | 5285 | 0.680 |
Why?
|
| Cannabinoids | 1 | 2020 | 38 | 0.680 |
Why?
|
| Cannabis | 1 | 2020 | 51 | 0.650 |
Why?
|
| Emetics | 6 | 2023 | 6 | 0.630 |
Why?
|
| Aged, 80 and over | 32 | 2018 | 5126 | 0.600 |
Why?
|
| Cyclophosphamide | 9 | 2023 | 75 | 0.590 |
Why?
|
| Drug Administration Schedule | 19 | 2011 | 284 | 0.580 |
Why?
|
| Practice Guidelines as Topic | 13 | 2021 | 705 | 0.570 |
Why?
|
| Neoplasm Invasiveness | 3 | 2007 | 248 | 0.570 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2014 | 805 | 0.560 |
Why?
|
| Carboplatin | 8 | 2023 | 40 | 0.550 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2016 | 140 | 0.540 |
Why?
|
| Adult | 48 | 2018 | 15693 | 0.540 |
Why?
|
| Colorectal Neoplasms | 4 | 2011 | 263 | 0.520 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2022 | 170 | 0.520 |
Why?
|
| Spiro Compounds | 1 | 2016 | 11 | 0.520 |
Why?
|
| Randomized Controlled Trials as Topic | 11 | 2023 | 678 | 0.520 |
Why?
|
| Taxoids | 4 | 2011 | 24 | 0.520 |
Why?
|
| Piperidines | 2 | 2011 | 55 | 0.500 |
Why?
|
| Consensus | 7 | 2023 | 193 | 0.490 |
Why?
|
| Neoplasm Staging | 12 | 2020 | 448 | 0.490 |
Why?
|
| Salvage Therapy | 4 | 2012 | 71 | 0.490 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2015 | 1511 | 0.460 |
Why?
|
| Clinical Trials as Topic | 10 | 2017 | 440 | 0.450 |
Why?
|
| Paclitaxel | 8 | 2022 | 90 | 0.420 |
Why?
|
| Guideline Adherence | 1 | 2015 | 295 | 0.410 |
Why?
|
| Radiation Oncology | 2 | 2024 | 51 | 0.410 |
Why?
|
| Radiography, Thoracic | 1 | 2013 | 111 | 0.410 |
Why?
|
| Infusions, Intravenous | 9 | 2011 | 163 | 0.410 |
Why?
|
| Serotonin 5-HT3 Receptor Antagonists | 6 | 2016 | 7 | 0.400 |
Why?
|
| Camptothecin | 2 | 2011 | 23 | 0.400 |
Why?
|
| Quinolizines | 6 | 1998 | 8 | 0.390 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2015 | 40 | 0.390 |
Why?
|
| Erlotinib Hydrochloride | 5 | 2018 | 18 | 0.390 |
Why?
|
| Vinblastine | 5 | 2011 | 18 | 0.390 |
Why?
|
| Mass Screening | 4 | 2015 | 648 | 0.390 |
Why?
|
| Deoxycytidine | 4 | 2018 | 40 | 0.380 |
Why?
|
| Indoles | 6 | 1998 | 106 | 0.370 |
Why?
|
| Piperazines | 1 | 2011 | 74 | 0.360 |
Why?
|
| Quinazolines | 3 | 2011 | 21 | 0.350 |
Why?
|
| Prognosis | 10 | 2021 | 1597 | 0.340 |
Why?
|
| Administration, Oral | 12 | 2014 | 355 | 0.330 |
Why?
|
| Radiotherapy | 7 | 2011 | 61 | 0.330 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2009 | 40 | 0.320 |
Why?
|
| Catheterization, Peripheral | 1 | 2009 | 46 | 0.320 |
Why?
|
| Imidazoles | 5 | 1992 | 77 | 0.320 |
Why?
|
| Receptors, Serotonin, 5-HT3 | 2 | 2006 | 2 | 0.320 |
Why?
|
| Anemia | 2 | 2015 | 119 | 0.310 |
Why?
|
| Journalism, Medical | 1 | 2008 | 4 | 0.310 |
Why?
|
| Substance P | 3 | 2004 | 44 | 0.300 |
Why?
|
| Hemorrhage | 1 | 2009 | 260 | 0.290 |
Why?
|
| Publishing | 1 | 2008 | 89 | 0.280 |
Why?
|
| Drug Combinations | 3 | 2016 | 147 | 0.270 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2006 | 39 | 0.270 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 1028 | 0.260 |
Why?
|
| Pilot Projects | 6 | 2016 | 915 | 0.260 |
Why?
|
| Embolization, Therapeutic | 1 | 2009 | 308 | 0.250 |
Why?
|
| Periodicals as Topic | 1 | 2008 | 166 | 0.250 |
Why?
|
| Palliative Care | 4 | 2020 | 214 | 0.250 |
Why?
|
| Prochlorperazine | 4 | 2000 | 5 | 0.250 |
Why?
|
| Time Factors | 6 | 2011 | 3620 | 0.240 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2022 | 237 | 0.240 |
Why?
|
| Maximum Tolerated Dose | 5 | 2007 | 38 | 0.240 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2006 | 168 | 0.240 |
Why?
|
| Adenocarcinoma | 4 | 2015 | 323 | 0.230 |
Why?
|
| Metoclopramide | 6 | 1996 | 12 | 0.230 |
Why?
|
| Survival Rate | 8 | 2011 | 801 | 0.230 |
Why?
|
| Evidence-Based Medicine | 4 | 2021 | 442 | 0.230 |
Why?
|
| Receptors, Neurokinin-1 | 2 | 2001 | 11 | 0.230 |
Why?
|
| Alopecia | 1 | 2004 | 25 | 0.230 |
Why?
|
| Body Image | 1 | 2004 | 29 | 0.230 |
Why?
|
| Prospective Studies | 7 | 2011 | 3069 | 0.220 |
Why?
|
| Injections, Intravenous | 10 | 2003 | 155 | 0.220 |
Why?
|
| Risk Factors | 7 | 2016 | 4990 | 0.220 |
Why?
|
| Sclerosis | 1 | 2003 | 7 | 0.220 |
Why?
|
| Erythropoietin | 1 | 2004 | 35 | 0.220 |
Why?
|
| Doxorubicin | 5 | 2011 | 97 | 0.220 |
Why?
|
| Mediastinal Neoplasms | 1 | 2003 | 17 | 0.220 |
Why?
|
| Lymphoma, B-Cell | 1 | 2003 | 59 | 0.210 |
Why?
|
| Breast Neoplasms | 5 | 2015 | 1118 | 0.210 |
Why?
|
| Early Detection of Cancer | 2 | 2017 | 266 | 0.210 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2003 | 65 | 0.210 |
Why?
|
| Neurotransmitter Agents | 1 | 2003 | 41 | 0.210 |
Why?
|
| Calcinosis | 1 | 2003 | 79 | 0.210 |
Why?
|
| Health Status | 1 | 2005 | 426 | 0.200 |
Why?
|
| Radiosurgery | 1 | 2023 | 61 | 0.200 |
Why?
|
| Anthracyclines | 2 | 2023 | 10 | 0.190 |
Why?
|
| Societies, Medical | 3 | 2021 | 338 | 0.190 |
Why?
|
| Incidence | 4 | 2014 | 1239 | 0.190 |
Why?
|
| Organoplatinum Compounds | 2 | 2011 | 17 | 0.190 |
Why?
|
| Drug Evaluation | 2 | 1998 | 19 | 0.180 |
Why?
|
| Cross-Over Studies | 2 | 2020 | 153 | 0.180 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 461 | 0.180 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2015 | 23 | 0.180 |
Why?
|
| Testicular Neoplasms | 3 | 1990 | 32 | 0.180 |
Why?
|
| Dronabinol | 1 | 2020 | 31 | 0.170 |
Why?
|
| Pemetrexed | 3 | 2022 | 11 | 0.170 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 104 | 0.170 |
Why?
|
| Acute Disease | 7 | 2005 | 659 | 0.170 |
Why?
|
| Survival Analysis | 4 | 2018 | 554 | 0.160 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 1990 | 8 | 0.160 |
Why?
|
| Benzene Derivatives | 1 | 1999 | 4 | 0.160 |
Why?
|
| United States | 7 | 2023 | 7429 | 0.160 |
Why?
|
| Plant Extracts | 1 | 2020 | 163 | 0.160 |
Why?
|
| Hospices | 2 | 2017 | 34 | 0.160 |
Why?
|
| Risk | 2 | 2016 | 364 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2001 | 328 | 0.150 |
Why?
|
| Drugs, Investigational | 1 | 1998 | 11 | 0.150 |
Why?
|
| Pyrrolidinones | 1 | 2018 | 11 | 0.150 |
Why?
|
| Quinolines | 1 | 2018 | 41 | 0.140 |
Why?
|
| Mutation | 3 | 2021 | 2458 | 0.140 |
Why?
|
| Placebos | 3 | 2006 | 68 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 179 | 0.140 |
Why?
|
| Drug Administration Routes | 4 | 2010 | 20 | 0.140 |
Why?
|
| Quality of Life | 1 | 2004 | 1138 | 0.140 |
Why?
|
| Serotonin | 3 | 2004 | 59 | 0.140 |
Why?
|
| Hospice Care | 1 | 2017 | 62 | 0.130 |
Why?
|
| Critical Care | 1 | 2020 | 399 | 0.130 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2015 | 490 | 0.130 |
Why?
|
| Age Factors | 4 | 2006 | 1505 | 0.130 |
Why?
|
| Fluorouracil | 3 | 2011 | 56 | 0.130 |
Why?
|
| Chemoprevention | 1 | 2016 | 39 | 0.130 |
Why?
|
| Esophageal Neoplasms | 3 | 2001 | 79 | 0.130 |
Why?
|
| Neutropenia | 5 | 2011 | 62 | 0.120 |
Why?
|
| Induction Chemotherapy | 1 | 2015 | 31 | 0.120 |
Why?
|
| Patient Selection | 2 | 2013 | 465 | 0.120 |
Why?
|
| Radiation-Sensitizing Agents | 3 | 2000 | 13 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2017 | 256 | 0.120 |
Why?
|
| Leucovorin | 2 | 2011 | 9 | 0.120 |
Why?
|
| Glucocorticoids | 2 | 2010 | 180 | 0.110 |
Why?
|
| ErbB Receptors | 2 | 2018 | 112 | 0.110 |
Why?
|
| Lung Diseases | 1 | 2015 | 170 | 0.110 |
Why?
|
| Diphtheria Toxin | 1 | 1993 | 4 | 0.110 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 1993 | 8 | 0.110 |
Why?
|
| Logistic Models | 2 | 2010 | 1235 | 0.100 |
Why?
|
| Combined Modality Therapy | 9 | 2001 | 354 | 0.100 |
Why?
|
| Interleukin-2 | 1 | 1993 | 164 | 0.100 |
Why?
|
| Smoking | 2 | 2014 | 826 | 0.100 |
Why?
|
| Remission Induction | 4 | 1997 | 137 | 0.100 |
Why?
|
| Algorithms | 1 | 1997 | 977 | 0.090 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 1991 | 19 | 0.090 |
Why?
|
| Area Under Curve | 1 | 2011 | 141 | 0.090 |
Why?
|
| Receptors, Serotonin | 3 | 1999 | 16 | 0.090 |
Why?
|
| Disease-Free Survival | 2 | 2011 | 228 | 0.090 |
Why?
|
| Sex Factors | 2 | 2006 | 935 | 0.090 |
Why?
|
| SEER Program | 1 | 2010 | 66 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 75 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2011 | 2338 | 0.080 |
Why?
|
| Stomach Neoplasms | 3 | 2000 | 69 | 0.080 |
Why?
|
| B7-H1 Antigen | 2 | 2022 | 54 | 0.080 |
Why?
|
| Retroperitoneal Space | 1 | 2009 | 19 | 0.080 |
Why?
|
| Glutamates | 1 | 2009 | 13 | 0.080 |
Why?
|
| Flank Pain | 1 | 2009 | 8 | 0.080 |
Why?
|
| Guanine | 1 | 2009 | 23 | 0.080 |
Why?
|
| Adrenal Glands | 1 | 2009 | 32 | 0.080 |
Why?
|
| Patient Safety | 1 | 2012 | 238 | 0.080 |
Why?
|
| Probability | 2 | 2006 | 168 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 3 | 2004 | 331 | 0.080 |
Why?
|
| Clinical Protocols | 1 | 2009 | 136 | 0.080 |
Why?
|
| Skin Neoplasms | 1 | 1993 | 398 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 527 | 0.070 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2000 | 31 | 0.070 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 903 | 0.070 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 1987 | 4 | 0.070 |
Why?
|
| Topotecan | 1 | 2006 | 5 | 0.070 |
Why?
|
| Diagnostic Imaging | 1 | 2009 | 243 | 0.070 |
Why?
|
| Karnofsky Performance Status | 1 | 2006 | 12 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2006 | 241 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2015 | 6077 | 0.060 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2004 | 12 | 0.060 |
Why?
|
| Darbepoetin alfa | 1 | 2004 | 4 | 0.060 |
Why?
|
| Steroids | 1 | 2023 | 52 | 0.050 |
Why?
|
| Receptor, ErbB-2 | 1 | 2004 | 49 | 0.050 |
Why?
|
| Immunophenotyping | 1 | 2003 | 184 | 0.050 |
Why?
|
| Mitomycin | 3 | 1994 | 24 | 0.050 |
Why?
|
| Methylprednisolone | 2 | 2000 | 32 | 0.050 |
Why?
|
| Hemoglobins | 1 | 2004 | 133 | 0.050 |
Why?
|
| Prodrugs | 1 | 2003 | 34 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2022 | 7 | 0.050 |
Why?
|
| Disease Progression | 1 | 2007 | 1119 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2000 | 30 | 0.050 |
Why?
|
| Lactams | 1 | 2022 | 18 | 0.050 |
Why?
|
| Aminopyridines | 1 | 2022 | 31 | 0.050 |
Why?
|
| Organophosphorus Compounds | 1 | 2022 | 31 | 0.050 |
Why?
|
| Body Weight | 1 | 2004 | 369 | 0.050 |
Why?
|
| Bevacizumab | 1 | 2022 | 57 | 0.050 |
Why?
|
| Etoposide | 3 | 1993 | 33 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2022 | 65 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2000 | 300 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2022 | 131 | 0.050 |
Why?
|
| Transplantation Conditioning | 1 | 2001 | 98 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2018 | 2376 | 0.050 |
Why?
|
| Anxiety | 1 | 2004 | 387 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 3 | 2005 | 130 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2017 | 217 | 0.040 |
Why?
|
| Adolescent | 4 | 2005 | 5842 | 0.040 |
Why?
|
| Bleomycin | 3 | 1989 | 32 | 0.040 |
Why?
|
| Digestive System Neoplasms | 1 | 1999 | 3 | 0.040 |
Why?
|
| Models, Biological | 1 | 2004 | 1143 | 0.040 |
Why?
|
| Acetals | 1 | 1999 | 1 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 154 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 55 | 0.040 |
Why?
|
| American Medical Association | 1 | 2017 | 6 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 836 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2017 | 35 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2000 | 288 | 0.040 |
Why?
|
| Depression | 1 | 2004 | 829 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2011 | 526 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 121 | 0.030 |
Why?
|
| Neoplasm Metastasis | 2 | 1987 | 186 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2016 | 6 | 0.030 |
Why?
|
| Massachusetts | 2 | 2014 | 2021 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1996 | 31 | 0.030 |
Why?
|
| Platinum | 1 | 2015 | 20 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2016 | 52 | 0.030 |
Why?
|
| Hamartoma | 1 | 2015 | 7 | 0.030 |
Why?
|
| Mediastinoscopy | 1 | 2015 | 7 | 0.030 |
Why?
|
| Thoracotomy | 1 | 2015 | 44 | 0.030 |
Why?
|
| Granuloma | 1 | 2015 | 41 | 0.030 |
Why?
|
| Headache | 1 | 1995 | 54 | 0.030 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2015 | 54 | 0.030 |
Why?
|
| Animals | 2 | 2008 | 19664 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 474 | 0.030 |
Why?
|
| Pleural Neoplasms | 1 | 1994 | 19 | 0.030 |
Why?
|
| Mesothelioma | 1 | 1994 | 27 | 0.030 |
Why?
|
| Chemoreceptor Cells | 1 | 1993 | 4 | 0.030 |
Why?
|
| Receptors, Neurotransmitter | 1 | 1993 | 17 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2014 | 244 | 0.030 |
Why?
|
| Age Distribution | 1 | 2014 | 249 | 0.030 |
Why?
|
| Proteomics | 1 | 2015 | 263 | 0.030 |
Why?
|
| Brain Stem | 1 | 1993 | 28 | 0.030 |
Why?
|
| Radiology Information Systems | 1 | 2013 | 31 | 0.030 |
Why?
|
| Models, Organizational | 1 | 2013 | 92 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2013 | 126 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 333 | 0.020 |
Why?
|
| Mucositis | 1 | 2011 | 7 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 1097 | 0.020 |
Why?
|
| Orchiectomy | 2 | 1989 | 28 | 0.020 |
Why?
|
| Bridged Bicyclo Compounds | 1 | 1991 | 2 | 0.020 |
Why?
|
| Tropanes | 1 | 1991 | 6 | 0.020 |
Why?
|
| Indazoles | 1 | 1991 | 12 | 0.020 |
Why?
|
| Diarrhea | 1 | 2011 | 75 | 0.020 |
Why?
|
| Levamisole | 1 | 1991 | 8 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 1078 | 0.020 |
Why?
|
| Benzamides | 1 | 1991 | 63 | 0.020 |
Why?
|
| BCG Vaccine | 1 | 1991 | 45 | 0.020 |
Why?
|
| Research Design | 1 | 1994 | 556 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 396 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 1990 | 74 | 0.020 |
Why?
|
| Dysgerminoma | 1 | 1989 | 2 | 0.020 |
Why?
|
| Chorionic Gonadotropin | 1 | 1989 | 14 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 1560 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 453 | 0.020 |
Why?
|
| Mitomycins | 1 | 1988 | 6 | 0.020 |
Why?
|
| Random Allocation | 1 | 1989 | 193 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2011 | 2517 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2013 | 649 | 0.020 |
Why?
|
| Medical History Taking | 1 | 1987 | 65 | 0.020 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1987 | 19 | 0.020 |
Why?
|
| Physical Examination | 1 | 1987 | 104 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2005 | 1926 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2007 | 115 | 0.020 |
Why?
|
| Registries | 1 | 1989 | 801 | 0.020 |
Why?
|
| Pain Management | 1 | 1987 | 146 | 0.020 |
Why?
|
| Epirubicin | 1 | 2005 | 2 | 0.020 |
Why?
|
| Reference Values | 1 | 2005 | 326 | 0.010 |
Why?
|
| Social Support | 1 | 1987 | 355 | 0.010 |
Why?
|
| Trastuzumab | 1 | 2004 | 11 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2004 | 152 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2005 | 717 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 851 | 0.010 |
Why?
|
| Esophagitis | 1 | 2001 | 9 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2000 | 81 | 0.010 |
Why?
|
| Radiography | 1 | 2000 | 516 | 0.010 |
Why?
|
| Demography | 1 | 1997 | 169 | 0.010 |
Why?
|
| Tamoxifen | 1 | 1996 | 35 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 1996 | 38 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 1999 | 415 | 0.010 |
Why?
|
| Asbestos | 1 | 1994 | 11 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 1994 | 99 | 0.010 |
Why?
|
| Mammography | 1 | 1996 | 271 | 0.010 |
Why?
|
| Environmental Exposure | 1 | 1994 | 208 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 1991 | 136 | 0.010 |
Why?
|
| alpha-Fetoproteins | 1 | 1989 | 15 | 0.010 |
Why?
|
| Postoperative Care | 1 | 1989 | 115 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1989 | 94 | 0.000 |
Why?
|